Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms

American Journal of Hematology

Volumn 84, Issue 2, 2009, Pages 126-127

  Fiorini, Alessia ^a   Chiusolo, Patrizia ^a   Rossi, Elena ^a   Za, Tommaso ^a   De Ritis, Daniela G ^a   Ciminello, Angela ^a   Leone, Giuseppe ^a   De Stefano, Valerio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MOLECULAR MARKER; PHOSPHOLIPID ANTIBODY;

ABSENCE; DIAGNOSTIC TEST; EXON; GENE MUTATION; GENETIC SCREENING; HEMATOLOGIC DISEASE; HEMODILUTION; HUMAN; HYPERSPLENISM; LABORATORY TEST; LETTER; LIVER VEIN THROMBOSIS; MUTATION; MYELOPROLIFERATIVE NEOPLASM; NEOPLASM; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PREVALENCE; PRIORITY JOURNAL; SPLANCHNIC VENOUS THROMBOSIS; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; BUDD-CHIARI SYNDROME; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENETIC SCREENING; HUMANS; JANUS KINASE 2; MALE; MESENTERIC VEINS; MIDDLE AGED; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PORTAL VEIN; SPLANCHNIC CIRCULATION; SPLENIC VEIN; THROMBOPHILIA; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 59949086226     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21335     Document Type: Letter

References (20)

1. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411-418.
2. Denninger MH, Chait Y, Casadevall N, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. Hepatology 2000; 31:587-591.
3. Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129:553-560.
4. Briere JB. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: Diagnosis and management. Semin Thromb Hemost 2006; 32:208-218.
5. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 2007; 110:1092-1097.
6. Boissinot M, Lippert E, Girodon F, et al. Latent myeloproliferative disorder revealed by the JAK2V617F-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108:3223-3224.
7. Gangat N, Wolanskyj A, Tefferi A. Abdominal vein thrombosis in essential thrombocythemia: Prevalence, clinical correlates, and prognostic implications. Eur J Haematol 2006; 77:327-333.
8. Patel RK, Lea NC, Heneghan MA, et al. Prevalence of the activating JAK2V617F tyrosine kinase mutation V617F in the Budd-Chiari sindrome. Gastroenterology 2006; 130:2031-2038.
9. Primignani M, Barosi G, Bergamaschi G, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44:1528-1534.
10. Smalberg JH, Murad SD, Braakman E, et al. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006; 91:1712-1713.
11. Colaizzo D, Amitrano L, Tiscia GL, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5:55-61.
12. De Stefano V, Fiorini A, Rossi E, et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5:708-714.
13. McMahon C, Abu-Elmagd K, Bontempo FA, et al. JAK2 V617F mutation in patients with catastrophic intra-abdominal thromboses. Am J Clin Pathol 2007; 127:736-743.
14. Regina S, Herault O, D' Alteroche L, et al. JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis. J Thromb Haemost 2007; 5:859-861.
15. Colaizzo D, Amitrano L, Tiscia GL, et al. Occurrence of the JAK2 V617F mutation in the Budd-Chiari sindrome. Blood Coagul Fibrinolysis 2008; 19:459-462.
16. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases. Blood 2008; 111:4922-4929.
17. Za T, Fiorini A, Rossi E, et al. Prevalence of the JAK2 V617F mutation in patients with unprovoked venous thromboembolism of common sites and without overt myeloproliferative neoplasms. Br J Haematol, doi: 10.1111/J.1365-2141. 2008.07537.x.
18. Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356:459-468.
19. Colaizzo D, Amitrano L, Tiscia GL, et al. A new JAK2 gene mutation in patients with polycythemia vera and splanchnic vein thrombosis. Blood 2007; 110:2768-2769.
20. Bergamaschi GM, Primignani M, Barosi G, et al. MPL and JAK2 V617F exon 12 mutations in patients with the Budd-Chiari sindrome or extrahepatic portal vein obstruction. Blood 2008; 111:4418.